Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business biotech financing

Solstice Oncology $225M Series A Launch

Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 11, 2026

Sentiment
15
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The launch and large Series A financing signal continued strong investor appetite for differentiated immuno-oncology assets, supporting valuations across the early-stage biotech sector. Harbour BioMed gains validation of its antibody platform and a partner to fund global development of porustobart, potentially improving its pipeline outlook and licensing revenue prospects.

biotechnology pharmaceuticals healthcare

Solstice Oncology, a clinical-stage immuno-oncology company focused on neoadjuvant cancer treatment, launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion Ventures and other investors. The company is advancing porustobart, a second-generation Fc-enhanced CTLA-4 antibody discovered and developed by Harbour BioMed, across two clinical indications, beginning with microsatellite-stable clinical stage II-III colon cancer. A Phase 2 trial evaluating porustobart in combination with pembrolizumab in the neoadjuvant setting will open for enrollment early in the fourth quarter of 2026, with data anticipated in the second half of 2027. In February 2026, Harbour BioMed entered into a license agreement and equity partnership with Solstice Oncology granting exclusive development and commercialization rights to porustobart outside Greater China. In an earlier Phase 2 study conducted by Harbour BioMed, porustobart combined with tislelizumab demonstrated a 30% objective response rate (7 of 23 patients) in late-line MSS metastatic colorectal cancer patients without liver metastases, with a median duration of response of 8.4 months and a favorable safety profile. Solstice Oncology is led by CEO Caroline Loew, while Harbour BioMed is led by Founder, Chairman and CEO Jingsong Wang. RA Capital Partner Josh Resnick and University of Leeds Professor Jenny Seligmann commented on the potential of the neoadjuvant approach.

95 Solstice Oncology launched with Series A financing
85 Harbour BioMed licensed porustobart Solstice Oncology
85 Solstice Oncology advanced porustobart into Phase 2
80 RA Capital Management led Series A financing Solstice Oncology
70 Harbour BioMed reported Phase 2 results
60 Canaan Partners participated in Series A financing Solstice Oncology
60 Forbion Ventures participated in Series A financing Solstice Oncology
priv
Solstice Oncology launched with a $225 million Series A financing and is advancing porustobart into a Phase 2 neoadjuvant colon cancer trial, positioning it as a well-funded clinical-stage immuno-oncology company.
Importance 100.0 Sentiment 40.0
priv
Harbour BioMed discovered and developed porustobart and licensed it to Solstice Oncology outside Greater China in February 2026; the launch and financing validate its antibody platform and could bring milestone and royalty revenue.
Importance 85.0 Sentiment 30.0
priv
RA Capital Management led the $225 million Series A financing, deepening its position in a promising immuno-oncology asset.
Importance 60.0 Sentiment 20.0
priv
Canaan Partners participated in the Series A financing, gaining exposure to the neoadjuvant immuno-oncology opportunity.
Importance 40.0 Sentiment 15.0
priv
Forbion Ventures participated in the Series A financing, adding a differentiated CTLA-4 asset to its portfolio.
Importance 40.0 Sentiment 15.0
per
As CEO of Solstice Oncology, Caroline Loew outlined the company's strategy of treating cancer earlier in the neoadjuvant setting.
Importance 35.0 Sentiment 10.0
per
As Founder, Chairman and CEO of Harbour BioMed, Jingsong Wang commented on the launch and the continued development of porustobart.
Importance 30.0 Sentiment 10.0
per
As a Partner at RA Capital, Josh Resnick expressed conviction in the science, strategy and team behind Solstice Oncology.
Importance 20.0 Sentiment 5.0
per
As a Professor at the University of Leeds, Jenny Seligmann commented on the potential of neoadjuvant approaches and pathologic response as an endpoint for porustobart in MSS colon cancer.
Importance 15.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.